GH1 and non-functioning pituitary adenoma: Median follow-up time was 5.2 (0.1–20.2) years, representing 4065 person-years of GH replacement therapy, for patients with previous NFPA, 6.1 (0.2–15.8) years, corresponding with 1104 treatment-years, for patients with previous CD and 3.1 (0.2–13.7) years, being 280 treatment-years, for patients with previous acromegaly (p < 0.001).